Teva/Barr let the competition continue
Teva will divest assets in 29 U.S. markets to settle Federal Trade Commission charges that the generic giant's $8.9 billion acquisition of rival firm Barr would be anticompetitive. The consent order requires Teva and Barr to sell assets of certain formulations of 16 overlapping on-market generic drugs, representing approximately $60 million in the companies' annual sales, and 13 overlapping pipeline generic drugs; drugs include those commonly used to treat acid reflux disease, cancer, bacterial infections, diabetes and depression. Assets will be divided between current generic competitors Watson and Qualitest
You may also be interested in...
Teva’s integration of Barr is ahead of schedule, enabling the generics firm to think about strengthening its branded franchises.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.